KPMA calls for more rational approach to new drug pricing policy

Published: 2006-08-10 06:59:00

Updated: 2006-08-10 06:59:00

The so-called positive list system reinforces the government's rash approach to shaping policies, according to the Korea Pharmaceutical Manufacturers Association (KPMA).

The KPMA said the ministry will have to overcome many problems to guarantee the success of the new drug pricing system.

T...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK